ArticleResearch square2025
Trajectories of Patient-Reported Outcomes among Diverse Cancer Patients in Ambulatory Oncology Clinics.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
10 authors.
Funding
Abstract
Purpose: Patient-reported outcomes (PROs) offer critical insights into cancer survivors' symptoms and health-related quality of life (HRQOL). This study evaluated longitudinal trajectories of PROs among cancer survivors across diverse cancer types and identified factors associated with symptom burden and HRQOL. Methods: We conducted a retrospective longitudinal observational study of 3,809 cancer survivors in ambulatory oncology clinics who completed electronic health record-integrated PRO assessments measuring anxiety, depression, pain interference, fatigue, and physical function, and HRQOL. Linear mixed-effect models evaluated PRO trajectories over time across seven common cancer types. Results: Survivors with gynecological cancers reported the highest symptom burden across multiple domains, particularly anxiety, pain interference, physical function, and fatigue. Male genital system cancer survivors consistently showed lower symptom burden and better HRQOL. Head and neck cancer survivors improved in pain interference, fatigue, physical function, and HRQOL over time compared to other cancer types, while gastrointestinal cancer survivors exhibited worsening HRQOL than hematologic and head and neck cancer survivors. Marital status and comorbidity burden were independent predictors for all PRO scores. Conclusions: PRO trajectories varied substantially by cancer types, underscoring the need for personalized, cancer-specific survivorship care strategies. Implications for Cancer Survivors: While standard follow-up may suffice for male genital system and head and neck cancer survivors, more intensive interventions may be required for gynecological and gastrointestinal cancer survivors to address persistent symptom burden. Routine, EHR-integrated PRO monitoring can identify cancer survivors at risk for persistent symptom burden, guiding timely, tailored interventions to improve long-term HRQOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.